SecSonar.com

Ardelyx, Inc. (ARDX)

Ardelyx, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Ardelyx, Inc. (ARDX) is a Biotechnology company based in US with a market capitalization of $1.5B. Revenue grew 22.1% year-over-year and free cash flow was negative at -$44M. This page tracks ARDX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 395 employees · IPO Jun 19, 2014

Valuation

Valuation & price

$6.23 · as of May 17, 2026 · -22.0% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

9.03

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$7.99$6.11$4.22Jul 25Dec 25Jul 26Jul 7, 25$4.35Jul 9, 25$4.60Jul 11, 25$4.49Jul 15, 25$4.50Jul 17, 25$4.52Jul 21, 25$4.42Jul 23, 25$4.39Jul 25, 25$4.29Jul 29, 25$4.22Jul 31, 25$4.24Aug 4, 25$4.39Aug 6, 25$5.20Aug 11, 25$5.40Aug 13, 25$5.75Aug 15, 25$5.97Aug 19, 25$5.86Aug 21, 25$6.11Aug 25, 25$6.06Aug 27, 25$6.19Aug 29, 25$6.36Sep 3, 25$6.51Sep 5, 25$6.52Sep 9, 25$6.56Sep 11, 25$6.68Sep 16, 25$6.42Sep 18, 25$6.42Sep 22, 25$6.22Sep 24, 25$6.15Sep 26, 25$5.54Sep 30, 25$5.51Oct 2, 25$5.25Oct 6, 25$5.20Oct 8, 25$5.06Oct 10, 25$4.94Oct 14, 25$5.01Oct 16, 25$5.05Oct 21, 25$5.29Oct 23, 25$5.06Oct 27, 25$5.10Oct 29, 25$4.96Oct 31, 25$6.06Nov 4, 25$5.60Nov 6, 25$5.65Nov 10, 25$5.65Nov 12, 25$6.04Nov 14, 25$5.86Nov 18, 25$5.81Nov 20, 25$5.55Nov 25, 25$5.72Nov 28, 25$5.80Dec 2, 25$5.54Dec 4, 25$5.92Dec 8, 25$5.88Dec 10, 25$5.92Dec 12, 25$6.21Dec 16, 25$6.00Dec 18, 25$5.68Dec 22, 25$5.84Dec 24, 25$5.99Dec 29, 25$5.78Jan 2, 26$6.15Jan 6, 26$5.56Jan 8, 26$7.00Jan 12, 26$7.36Jan 14, 26$6.89Jan 16, 26$6.75Jan 21, 26$7.99Jan 23, 26$7.77Jan 27, 26$7.89Jan 29, 26$7.85Feb 2, 26$7.79Feb 4, 26$7.38Feb 9, 26$7.33Feb 11, 26$7.26Feb 13, 26$6.87Feb 18, 26$6.72Feb 20, 26$5.73Feb 24, 26$6.56Feb 26, 26$6.63Mar 2, 26$6.47Mar 4, 26$6.65Mar 6, 26$6.19Mar 10, 26$6.12Mar 12, 26$5.66Mar 17, 26$5.83Mar 19, 26$5.50Mar 23, 26$5.31Mar 25, 26$5.64Mar 27, 26$5.48Mar 31, 26$5.99Apr 2, 26$5.94Apr 7, 26$5.95Apr 9, 26$6.13Apr 13, 26$6.33Apr 15, 26$6.30Apr 17, 26$6.45Apr 22, 26$6.02Apr 24, 26$5.95Apr 28, 26$5.97Apr 30, 26$6.33May 4, 26$7.30May 6, 26$7.10May 8, 26$6.78May 12, 26$6.61May 14, 26$6.46May 18, 26$6.11May 20, 26$6.27May 22, 26$6.11May 28, 26$6.25Jun 1, 26$5.73Jun 3, 26$5.42Jun 5, 26$5.56Jun 9, 26$5.60Jun 11, 26$5.79Jun 15, 26$5.69Jun 17, 26$5.84Jun 22, 26$6.37Jun 24, 26$6.19Jun 26, 26$5.55Jul 2, 26$5.16
$4.2252-week range$7.99
Loading valuation history…

Fundamentals

Key fundamentals

$1.5B

Market cap

22.1%

Revenue growth (YoY)

89.5%

Gross margin

-$44M

Free cash flow (USD)

-$53.1M

Net debt

Net cash position

2.5%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$24.0MFY 2017$42.0MFY 2018$2.6MFY 2019$5.3MFY 2020$7.6MFY 2021$10.1MFY 2022$52.2MFY 2023$124.5MFY 2024$333.6MFY 2025$407.3M
$24M$407.3M

Free cash flow by year

2016 → 2025

FY 2016$-97.4MFY 2017$-67.5MFY 2018$-70.6MFY 2019$-76.8MFY 2020$-81.8MFY 2021$-154.4MFY 2022$-70.1MFY 2023$-90.1MFY 2024$-45.8MFY 2025$-44.0M
-$97.4M-$44M

Gross margin by year

2021 → 2025

FY 202190.1%FY 202292.1%FY 202385.7%FY 202484.8%FY 202589.5%
90.1%89.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

12

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventDebt FinancingJul 2, 2026Filing
  • Insider sellInsider Sell $490K · 10b5-1 PlanWilliams Laura A · Chief Patient Officer · $490.5KJun 22, 2026Filing
  • Insider sellInsider Sell $236K · 10b5-1 PlanRAAB MICHAEL · Director, President & CEO · $236.3KJun 17, 2026Filing
  • 8-K eventEquity Plan Amendment ApprovedJun 17, 2026Filing
  • Insider sellInsider Sell $343KRAAB MICHAEL · Director, President & CEO · $343.1KMay 22, 2026Filing
  • Insider sellInsider Sell $44KWilliams Laura A · Chief Patient Officer · $43.8KMay 22, 2026Filing
  • Insider sellInsider Sell $45KKelliher Mike · Chief Business Officer · $45.4KMay 22, 2026Filing
  • Insider sellInsider Sell $50KFoster Eric Duane · Chief Commercial Officer · $50.1KMay 22, 2026Filing
  • Insider sellInsider Sell $12KBrady James Parker · Chief Human Resources Officer · $11.6KMay 22, 2026Filing
  • Insider sellInsider Sell $14KBishop John E · See Remarks · $14.5KMay 22, 2026Filing

Questions

Frequently asked questions

What is Ardelyx, Inc.'s market cap?

Ardelyx, Inc. (ARDX) has a market capitalization of $1.5B.

What is ARDX's P/E ratio?

A meaningful P/E ratio is not available for ARDX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ARDX's price-to-book (P/B) ratio?

ARDX trades at 9.03 times book value per share.

Are insiders buying ARDX stock?

SEC Form 4 filings show no open-market insider buys at Ardelyx, Inc. in the last 90 days (12 sells).

Same arena

Related companies in Biotechnology

INBX

Inhibrx Biosciences, Inc.

$1.5B

IMTX

Immatics N.V.

$1.5B

MAZE

Maze Therapeutics, Inc.

$1.5B

TSHA

Taysha Gene Therapies, Inc.

$1.5B

NRIX

Nurix Therapeutics, Inc.

$1.5B

IMCR

Immunocore Holdings plc

$1.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.